Total of 3.4 million, nice! WebBroker Alert
========================
Avivagen Announces Second Closing of Private Placement
tnw
(via Thenewswire.ca)
OTTAWA, ONTARIO, November 14, 2013 -
Avivagen Inc. (TSXV:VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces a second closing of its previously announced private placement.
"Avivagen believes that a strong balance sheet will assist in securing global development, marketing and distribution arrangements for our products: Potential business partners need to know that Avivagen can follow-through on its commitments." stated C.E.O. & President Cameron Groome. "Combining the amount raised in our first closing in October with this second closing, Avivagen has raised a total of 3.42 million dollars - more than double our minimum targeted amount. We now look forward to realizing our major corporate objectives." concluded Mr. Groome.
The private placement second closing of $1,345,747.97 was comprised of the sale of 19,224,971 units with each unit being comprised of one common share and one-half of a common share purchase warrant, for a unit price of $0.07. Each whole warrant entitles the holder to acquire one common share of Avivagen at an additional purchase price of $0.12 for three years from closing.
Avivagen paid a total of $55,387.40 in cash and issued a total of 1,582,497 common share purchase warrants to finders in connection with the private placement. Each finders' warrant is exercisable into one common share of the Company for a period of two years at a price of $0.10 per share.
All securities issued via this placement are subject to statutory hold period expiring on March 14, 2014.
The private placement remains subject to TSX Venture Exchange approval.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker
symbol "VIV". The Company's goal is to develop and deliver scientifically-proven solutions that can truly benefit companion and production animals by employing natural mechanisms for maintaining good health. Avivagen's targeted markets include Pet Wellness and Livestock Productivity.
The company has sites located in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island.
More information can be found at
www.avivagen.com
.
About OxC-
beta
Avivagen
's proprietary and patent-protected technology is based on its discoveries concerning carotenoid antioxidants. The novel natural compounds discovered by Avivagen support the body's own systems to maintain and enhance health, particularly by supporting immune function. Avivagen's commercial-stage application of its technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta compounds occur naturally as carotenoid oxidation products in vegetation, but in minute amounts. They have been developed to support the health of companion animals and for use in the global food animal market.
Research results indicate OxC-beta supports innate immune function, which can help maintain good health. In pets, OxC-beta supports overall vitality and energy, mobility and joint function, skin, coat and gut. Results observed in food animals have included healthier growth, better utilization of feed and decreased mortality. In food animals, it is intended that use of OxC-beta avoids the feeding of antibiotics.
The commercial products of Avivagen are
Oximunol(TM) Chewables, OxC-beta for livestock and Vivamune(TM) Health Chews.
About Vivamune
(TM) Health Chews - "For dogs that dig life" and "For extraordinary cats"
Vivamune(TM) Health Chews, containing
Avivagen's proprietary active ingredients, are scientifically-formulated chews for dogs and cats. Vivamune(TM) Health Chews work with a pet's own immune system to maintain overall health and well-being. They are sold in re-sealable packages of 30 chews and are currently available in the United States by ordering on-line at
www.vivamunehealth.com
.
About Oximunol(TM) Chewables - "Optimized Health in a Chewable Tablet"
Oximunol(TM) Chewables
are scientifically-formulated chewable tablets that contain Avivagen's proprietary, patented active ingredient OxC-beta. OxC-beta has been shown to stimulate innate cellular immunity and may thereby help to maintain overall health and well-being. Oximunol(TM) Chewables are distributed by Bayer Healthcare LLC and are available through veterinarians for dogs of all ages in the United States.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0 or 5.0 Kg quantities for parts-per-million addition to animal feeds, in accordance with producer-developed protocols. In past studies, OxC-beta has been shown to support health and growth in species such as fish, chicken, pigs and cattle. OxC-beta for livestock is currently available for commercial sale in the Kingdom of Thailand.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
Phone: 613-949-8164
c.groome
@avivagen.com
Copyright (c) 2013 TheNewswire - All rights reserved.
----------------------------------------------------
Thank you for choosing TD Waterhouse. At TD Waterhouse, we are committed to providing you with the information, tools and resources you need to stay on top of the markets and invest with confidence.
To change your alert settings or to unsubscribe from the alerts service, please login to WebBroker.
TD Waterhouse Canada Inc. is a subsidiary of The Toronto-Dominion Bank. TD Waterhouse Canada Inc. - Member of the Canadian Investor Protection Fund. These products and/or services are only offered in jurisdictions where they may be lawfully offered for sale.
----------------------------------------------------
(c) 2013 CTVglobemedia Publishing Inc. All rights reserved.